Therapeutic Areas

From cardiovascular health to oncology, Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases. We also offer support services such as diagnostic clinics, educational seminars and digital tools to help patients better manage their health.

We offer a broad and diverse range of treatment options across all our therapeutic areas, with many categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment.

Cardiovascular

Infectious disease

Oncology

Immunology

CNS and anesthesia

Women's healthcare

Diabetes and metabolism

Gastroenterology

Respiratory and allergy

Dermatology

We are committed to meaningfully reducing the burden of both noncommunicable and infectious diseases by leveraging our scientific, medical, manufacturing and commercial expertise to develop holistic, integrated solutions for diagnosis, prevention and treatment of these conditions.

Easing the burden of noncommunicable diseases

According to the World Health Organization (WHO), noncommunicable diseases (NCDs), such as ischemic heart disease, stroke, diabetes, certain cancers and chronic obstructive pulmonary disease, were among the leading causes of death globally as of 2016.1 NCDs affect people of every age, gender and socioeconomic status in every corner of the world, and pose a heavy burden on individuals, families and communities. To overcome this global public health threat, patients worldwide need a partner they can trust – one that not only believes everyone deserves good health, but also has the portfolio, experience and expertise to make this belief a reality.

 

Helping hearts stay healthier

According to the WHO, coronary heart disease is the number one cause of death globally.1 Viatris collaborates with many organizations to help prevent, diagnose and treat many cardiovascular illnesses. Our deep experience in emerging and developed markets affords a tried-and-true method of achieving high impact across the patient experience, from awareness to adherence. In close collaboration with government, healthcare providers, technology partners and patients, we at Viatris will work to nurture healthcare systems that can adapt and respond to patients’ ever-changing needs. We continue to collaborate with medical associations, patient advocacy groups and academia to develop innovative, integrated solutions and programs to help strengthen both the delivery and quality of healthcare – ultimately, to reduce the burden of NCDs.

 

Select examples of our partnerships include:

  • The “Bending the Curve” program in China, a collaboration with the Cardiovascular Physician Branch of the Chinese Medical Doctor Association which provides comprehensive lipid screening, diagnosis and education.
  • The American College of Cardiology (ACC) Global Prevention Program, a partnership that aims to stem the rising tide of cardiovascular disease and reinforce best practices in treating patients along the cardiovascular continuum. Since its launch, the program has hosted 44 webinars, equipping more than 70,000 clinicians with the latest science, technology, resources and tools, and has reached approximately 230 million patients across China, Russia, Argentina, Mexico, Saudi Arabia, Egypt, United Arab Emirates, Malaysia, Indonesia and Vietnam
  • The NCD Academy, a novel web-based platform developed in partnership with the American College of Cardiology (ACC), the World Heart Federation (WHF) and the NCD Alliance (NCDA), which provides healthcare professionals with educational resources to enhance their clinical skills and improve knowledge on overall NCD management. The program will enable physicians and global health authorities to develop data driven NCD mitigation strategies that can ultimately help improve health outcomes
  • Partnering with the European Atherosclerosis Society to provide important education to physicians across Europe

1“Causes of Death.” World Health Organization. World Health Organization. Accessed June 8, 2020. https://www.who.int/data/gho/data/themes/topics/causes-of-death/GHO/causes-of-death.

Fighting infectious disease

We are also a global leader in treating infectious diseases such as HIV/AIDS, hepatitis and tuberculosis, and offer an extensive portfolio across these disease states. While many important strides have been made to treat these illnesses, there is still more to be done, especially in low- and lower-middle-income countries, where lack of access to therapeutics, preventative treatment and diagnostics often result in patients not receiving proper care. High-income countries face infectious disease challenges as well, where HIV transmission continues thirty years into the epidemic. From manufacturing a pediatric-friendly antiretroviral used to treat HIV-positive infants to providing HIV self-tests in some low- and middle-income countries, we are innovating to help patients.

~40%

Our HIV products

of the 23.3 million people on treatment for HIV use a Viatris product.

We manufacture ~5 billion ARV tablets and capsules every year and about 50% of our company’s total active pharmaceutical ingredient (API) capacity is devoted to ARVs.

Select Viatris infectious disease initiatives include

  • Collaborating with Otsuka and TB Alliance to increase access to effective antimicrobials for multi-drug resistant (MDR) and extensively drug resistant (XDR) forms of tuberculosis in high-burden countries
  • Being first-to-market with a next-generation HIV treatment, and partnering with UNAIDS, the United States President’s Emergency Plan for AIDS Relief (PEPFAR), and others, to make it available at low cost to public sector purchasers in low- and middle-income countries around the world
  • Developing a child-friendly formulation of the WHO’s preferred pediatric HIV treatment
  • Launching the first pan-genotypic treatment regimen for hepatitis C approved by the WHO pre-qualification of medicines program